Changes in Breast Cancer Incidence in Geneva and Hormone Replacement Therapy
Author Information
Author(s): Christine Bouchardy, Alfredo Morabia, Helena M Verkooijen, Gérald Fioretta, Yves Wespi, Peter Schäfer
Primary Institution: Geneva Cancer Registry, Institute for Social and Preventive Medicine, Geneva University
Hypothesis
The study investigates the relationship between hormone replacement therapy use and changes in age-specific breast cancer incidence in Geneva.
Conclusion
The increase in hormone replacement therapy use during the 1990s likely explains the significant change in breast cancer incidence patterns, with earlier diagnoses in younger women.
Supporting Evidence
- Breast cancer risk increased with age until 1997, after which the incidence peaked at 60-64 years.
- The incidence peak was primarily observed among women who used hormone replacement therapy.
- The proportion of early-stage breast cancer diagnoses increased significantly after 1997.
Takeaway
This study found that more women in Geneva are getting diagnosed with breast cancer at a younger age, possibly because of hormone replacement therapy.
Methodology
Population-based data from the Geneva cancer registry and a prospective study on hormone replacement therapy were analyzed using generalized log linear regression.
Potential Biases
Selection bias may exist as the study population may not be completely representative of all breast cancer patients.
Limitations
Information on hormone replacement therapy use was only available for about 50% of the women diagnosed, which may not fully represent the entire population.
Participant Demographics
The study included 8045 invasive breast cancer cases diagnosed between 1975–2003, with a focus on women aged 50–74 years for hormone replacement therapy data.
Statistical Information
P-Value
p < 0.001
Statistical Significance
p < 0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website